Novo Nordisk to slash Wegovy, Ozempic US list prices by up to 50%

Nordisk on Tuesday stated it plans to slash the monthly list prices of its standard weight problems and diabetes medication within the US by up to 50% beginning in 2027, in a bid to make the remedies extra accessible to sufferers with insurance coverage protection.

The weight problems injection Wegovy, its new pill counterpart, the diabetes shot Ozempic and the oral diabetes drug Rybelsus can have a brand new decrease list value of $675 per thirty days beginning on Jan. 1, 2027. The Wegovy medicines each at the moment have list prices of round $1,350 per thirty days, whereas the diabetes medication have list prices of round $1,027 per thirty days.

For the primary time, Novo stated its value cuts are focusing on insured sufferers whose out-of-pocket prices are linked to list prices, equivalent to individuals with high-deductible well being plans or coinsurance profit designs.

“Both of these patient populations should, beginning [in 2027]see a benefit with lower out-of-pocket burdens,” Jamey Millar, the corporate’s head of US operations, informed CNBC in an interview.

He added that Novo expects enhancements in entry and uptake amongst sufferers within the industrial insurance coverage market, though the corporate isn’t giving any particular expectations.

The transfer may assist Novo compete higher with Eli Lillywhich now holds the bulk share within the blockbuster GLP-1 market. Lilly’s more practical medication and earlier foray into the direct-to-consumer area have allowed it to take the lead within the area, however the firm has but to considerably decrease the US list prices of its medicines.

It’s unclear precisely how a lot industrial insured sufferers sometimes pay out of pocket for Novo’s medication. Those sufferers could pay as little as $25 per thirty days for Novo’s medication in “only the best of circumstances,” Millar stated.

But sufferers in high-deductible plans would have to pay out of pocket “more or less the full list price of a drug until they reach that” threshold and the insurance coverage profit kicks in, he added. Millar stated a few of these sufferers defer therapy totally as a result of they do not need to shoulder that expense. The variety of sufferers utilizing high-deductible plans has elevated over time due to the trade-off of decrease premiums, he famous.

Meanwhile, Millar stated different individuals have 25% to 33% of their coinsurance linked to the list prices of these medication.

The Danish drugmaker has beforehand lower the direct-to-consumer prices of Wegovy and Ozempic, which primarily profit cash-paying sufferers who usually do not have insurance coverage protection for the medication.

Novo gives its medication to cash-paying sufferers for $149 to $499 per thirty days, relying on the particular product and dosage. Novo and Lilly have escalated a GLP-1 pricing struggle over the past yr, particularly following the landmark “most favored nation” offers they struck with President Donald Trump in November.

The transfer additionally coincides with new, decrease Medicare prices going into impact for Novo’s weight problems and diabetes medication in 2027 following negotiations with the federal authorities beneath the Inflation Reduction Act. The new negotiated prices for Wegovy, Ozempic and Rybelsus shall be $274 per thirty days.